Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | MAX | P61244 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15648557 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL29376725 | 0.80 | NCF1 (0.50) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL461111 | 0.80 | NCF1 (0.50) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL4048229 | 0.77 | POLB (0.48) | MYCMAXKDM4EALDH1A1TRPM4 | |
| SCHEMBL5421698 | 0.76 | LMNA (0.53) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4264710 | 0.76 | KDM4E (0.46) | MYCMAXKDM4EALDH1A1RAB9A | |
| SCHEMBL472912 | 0.75 | MEN1 (0.42) | KDM4EALDH1A1RAB9AGABRA1GABRB2 | |
| SCHEMBL27311485 | 0.75 | MEN1 (0.48) | MYCMAXKDM4EALDH1A1MEN1 | |
| SCHEMBL7420683 | 0.75 | KDM4E (0.65) | MYCMAXKDM4EALDH1A1MEN1 | |
| SCHEMBL8600823 | 0.74 | KMT2A (0.43) | ALDH1A1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018195536-A1 | ANTIBACTERIAL COMPOUNDS | YU SHEN (US) | 2018-10-25 | — | — | WO | claimed |
| US-8906602-B2 | Methods for identifying candidate compounds for treating, reducing, or preventing pathogenic infections | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-09 | — | — | US | claimed |
| US-20140018312-A1 | STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AGAINST ELECTRON TRANSPORT-DEFICIENT MICROBES AND AS POTENTIATORS FOR ANTIMICROBIAL AGENTS AGAINST PATHOGENIC BACTERIA | SOCPRA SCIENCES ET GENIE, S.E.C. (CA) | 2014-01-16 | — | — | US | claimed |
| EP-2675822-A1 | STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AGAINST ELECTRON TRANSPORT-DEFICIENT MICROBES AND AS POTENTIATORS FOR ANTIMICROBIAL AGENTS AGAINST PATHOGENIC BACTERIA | Socpra-Sciences Et Génie S.E.C. (CA) | 2013-12-25 | — | — | EP | claimed |
| WO-2012109752-A1 | STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AGAINST ELECTRON TRANSPORT-DEFICIENT MICROBES AND AS POTENTIATORS FOR ANTIMICROBIAL AGENTS AGAINST PATHOGENIC BACTERIA | SOCPRA SCIENCES ET GÉNIE, S.E.C. (CA) | 2012-08-23 | — | — | WO | claimed |
| US-20080207673-A1 | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins | XILINAS MICHEL | 2008-08-28 | — | — | US | claimed |
| US-20070292851-A1 | Methods for Identifying Candidate Compounds for Treating, Reducing, or Preventing Pathogenic Infections | THE GENERAL HOSPITAL CORPORATION | 2007-12-20 | — | — | US | claimed |
| US-20070099889-A1 | Use of pseudan and pseudan inclusion bodies | GEORGE MASON INTELLECTUAL PROPERTIES, INC. | 2007-05-03 | — | — | US | claimed |
| WO-2007008769-A2 | USE OF PSEUDAN AND PSEUDAN INCLUSION BODIES | GEORGE MASON UNIVERSITY (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006117660-A2 | METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS | CLIO PHARMACEUTICAL CORPORATION (US) | 2006-11-09 | — | — | WO | claimed |
| WO-2005069989-A2 | METHODS FOR IDENTIFYING CANDIDATE COMPOUNDS FOR TREATING, REDUCING, OR PREVENTING PATHOGENIC INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-04 | — | — | WO | claimed |
| US-20030109548-A1 | Compositions and methods of treating iron excess | ROYT PAULETTE W (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003041709-A1 | COMPOSITIONS AND METHODS OF TREATING IRON EXCESS | GEORGE MASON UNIVERSITY (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2024148322-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEARING DISORDERS | GATEWAY BIOTECHNOLOGY, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240218373-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | AIM IMMUNOTECH INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4388101-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE | AIM ImmunoTech Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2003037259-A2 | METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003000018-A2 | DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002051415-A2 | USE OF SEQUESTRANTS FOR TREATING PRION DISEASES | XILINAS MICHEL (CY) | 2002-07-04 | — | — | WO | disclosed |
| WO-1995028929-A1 | AMINOLINE-N-OXIDE ANTIMICROBIALS FOR USE AGAINST H. PYLORI INFECTIONS | RPMS TECHNOLOGY LIMITED (GB) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018312-A1 | STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AGAINST ELECTRON TRANSPORT-DEFICIENT MICROBES AND AS POTENTIATORS FOR ANTIMICROBIAL AGENTS AGAINST PATHOGENIC BACTERIA | TOMM70, TIMM50, TIMM10 | MYC 2471/4885MAX 4280/4885KDM4E 4417/4885 |
| US-20070099889-A1 | Use of pseudan and pseudan inclusion bodies | MMP8, ETF1, MMP1 | MYC 969/4885MAX 2093/4885KDM4E 3129/4885 |
| US-20240218373-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | ELAVL1, ELAVL3, SYNCRIP | MYC 2223/4885MAX 3967/4885KDM4E 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.